Estimated reading time: 2 minutes
AECI Limited, a leading mining explosives and chemicals company in Africa, recently announced the signing of an agreement for the sale of its Animal Health business, as a going concern, to Nutreco whose South African subsidiary is Trouw Nutrition South Africa.
This strategic move aligns with our recently announced strategy to streamline operations and focus on our core competencies, ensuring continuous growth and value creation for our stakeholders. Nutreco is recognised worldwide for its commitment to excellence and innovation, making it the right home for the Animal Health business and our people.
Holger Riemensperger, group CEO of AECI, commented: “We are pleased to have found a partner that shares our vision and values in Nutreco. This transaction represents a significant milestone in our journey, and we are confident that the Animal Health business will thrive under Nutreco’s leadership.”
The transaction is subject to customary closing conditions, including regulatory approvals and the satisfaction of other agreed-upon terms. We anticipate the transaction to close in four to six months.
We remain focussed on the successful execution of our strategy. This transaction affords us the opportunity to concentrate our efforts and resources on doubling the profitability of the core business (mining and chemicals) by 2026. Additionally, we aim to secure the third position globally in the mining market by 2030. – AECI Animal Health
Animal health importation case settled
The South African Health Products Regulatory Authority (SAHPRA) and V-Tech, a South African veterinary compounding company, has reached an agreement over the import of trilostane, an active ingredient used in the manufacturing of Cushing’s Disease medication. According to V-Tech, around 6 000 South African dogs suffer from Cushing’s Disease.
Earlier this month AgriOrbit reported on V-Tech’s struggle to import a consignment of trilostane that was stuck at OR Tambo International Airport since June this year. At the time, SAHPRA refused to release the shipment to V-Tech because this active pharmaceutical ingredient (API) was not present in any another registered medicine in South Africa. V-Tech, which has been importing the substance for a decade, maintained that trilostane was never called up for registration and therefore certain provisions of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) did not apply.
